The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Health Canada approves zanubrutinib plus obinutuzumab for adult patients with R/R FL
On February 7, 2024, Health Canada approved zanubrutinib, a Bruton’s tyrosine kinase inhibitor, in combination with obinutuzumab, an antibody therapy, for the treatment of adult patients with relapsed/refractory Grade 1–3a follicular lymphoma after ≥2 systemic therapies. This approval is based on positive results from the pivotal phase II ROSEWOOD trial.
The ROSEWOOD trial1
The ROSEWOOD trial (NCT03332017) is a global, open-label study investigating zanubrutinib plus obinutuzumab vs obinutuzumab alone. The trial met its primary endpoint with a significantly higher objective response rate in the zanubrutinib plus obinutuzumab arm. The Lymphoma Hub previously reported the trial design and promising results (Figure 1).
Figure 1. Median progression-free survival in zanubrutinib plus obinutuzumab vs obinutuzumab arm.*
*Data from Newswire.1
Conclusion1
The approval of zanubrutinib plus obinutuzumab in Canada provides patients with the first and only Bruton’s tyrosine kinase inhibitor for the treatment of follicular lymphoma.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content